ANTH on NASDAQ
Anthera Pharmaceuticals
Logo: Non-free logo, via Wikipedia5
American biopharmaceutical company
Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases.3 From Wikipedia, CC BY-SA 4.0
$0.00 up 0.00 (0.00%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 18, 2026.
Overview
- TickerANTH on NASDAQ1
- Industrypharmaceutical industry1
- HeadquartersHayward1
- Websitewww.anthera.com
- Legal formDelaware corporation1
- Incorporated inDE6
- Business address25801 Industrial Boulevard, Suite B, Hayward, Ca 945456
- Filer categorySmaller reporting company6
See how the biggest companies compare on our leaderboards
Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase (Sollpura), Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency (EPI) is currently in Phase 3 clinical trials, and A-623 (Blisibimod) for the treatment of IgA nephropathy is currently in Phase 2 clinical trial.3
Leadership
Who has led Anthera Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
President
Chief financial officer
- Chief executive officerPaul F. Truex Feb 23, 2010 to Sep 22, 20168
- ChairPaul F. Truex Dec 6, 2016 to Dec 6, 20169
- PresidentPaul F. Truex Feb 23, 2010 to Sep 18, 20158
- Chief financial officerChristopher P. Lowe Feb 23, 2010 to May 21, 201310
Board members and other officers (27)
- Chief Liquidating OfficerMark Drew McManigle Sep 12, 2018 to Sep 12, 201811
- Executive ChaimanPaul F. Truex May 19, 2017 to May 19, 201712
- SVP & Chief Regulatory OfficerKlara Dickinson Jun 2, 2015 to May 22, 201713
- Chief Accounting OfficerMay Liu May 28, 2013 to Jan 9, 201814
- VP of Administration and CBOChristopher P. Lowe Feb 14, 2011 to Jan 7, 201315
- Sr. VP, Cardiovasc. Prod.Colin Hislop Feb 23, 2010 to Feb 16, 201616
- VP, Pharmaceutical R&DDebra Odink Feb 23, 2010 to Oct 13, 201517
- Chief Medical Officer & Ex. VPJames E. Pennington Feb 23, 2010 to Feb 23, 201018
- SR VP, Preclinical DevelopmentJoaquim Trias Feb 23, 2010 to Sep 23, 201019
- VP, Corp. & Business Dev.Stephen Lau Feb 23, 2010 to Jul 2, 201020
- VP, Glob. Reg. and ComplianceUrsula Fritsch Feb 23, 2010 to Jul 2, 201021
- SVP, Prod. Dev. & Project MngmGeorgina Kilfoil Mar 26, 2010 to Jan 7, 201322
- Board memberMark Drew McManigle Sep 12, 2018 to Sep 12, 201811
- Board memberBrent Furse Apr 29, 2016 to Jan 9, 201823
- Board memberSteven B. Engle Apr 23, 2014 to Apr 29, 201624
- Board memberPhilip Sager Jun 16, 2014 to Jan 9, 201825
- Board memberSanford S. Zweifach Apr 3, 2013 to May 22, 201526
- Board memberBogdan Dziurzynski Mar 8, 2012 to Jun 4, 201327
- Board memberDebra Odink Apr 14, 2011 to Apr 14, 201128
- Board memberSamuel D. Isaly May 11, 2011 to Feb 1, 201329
- Board memberA. Rachel Leheny Feb 23, 2010 to Oct 4, 201030
- Board memberAnnette Bianchi Feb 23, 2010 to May 13, 201131
- Board memberChristopher S. Henney Feb 23, 2010 to Jan 9, 201832
- Board memberDaniel K. Spiegelman Feb 23, 2010 to Jun 16, 201433
- Board memberDonald J. Santel Feb 23, 2010 to Jul 5, 201134
- Board memberJames Healy Feb 23, 2010 to May 20, 201335
- Board memberPaul F. Truex Feb 23, 2010 to Jan 9, 20188
Products and brands
Blisibimod
Blisibimod is a selective peptibody antagonist of B-cell activating factor (BAFF). BAFF is critical to the development, maintenance and survival of B-cells, but is known to be up-regulated in autoimmune diseases. It is primarily expressed by macrophages, monocytes and dendritic cells. Blisibimod binds to BAFF and inhibits the interaction of BAFF with its receptors. Blisibimod is currently being evaluated in IgA nephropathy.
Sollpura
In July 2014, Anthera acquired Sollpura (Liprotamase) from Eli Lilly and Company. Sollpura is an investigational pancreatic enzyme replacement therapy (PERT) that uses three biotechnology-derived digestive enzymes intended to treat patients with endocrine pancreatic insufficiency as a result of cystic fibrosis and other diseases.
From Wikipedia’s article on Anthera Pharmaceuticals, shared under CC BY-SA 4.0.7
Timeline
Links
- Websitewww.anthera.com1
- WikipediaAnthera Pharmaceuticals
- WikidataQ4771754
- SEC EDGARCIK 1316175
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3WikipediaAnthera Pharmaceuticals on Wikipedia
- 4Yahoo FinanceANTH quote
- 5Wikimedia CommonsAnthera Pharmaceuticals logo by unknown, Non-free logo
- 6
- 7
- 8
- 9SEC EDGARPaul F. Truex, Chair
- 10
- 11
- 12SEC EDGARPaul F. Truex, Executive Chaiman
- 13
- 14SEC EDGARMay Liu, Chief Accounting Officer
- 15
- 16
- 17SEC EDGARDebra Odink, VP, Pharmaceutical R&D
- 18
- 19
- 20
- 21
- 22
- 23SEC EDGARBrent Furse, Board member
- 24SEC EDGARSteven B. Engle, Board member
- 25SEC EDGARPhilip Sager, Board member
- 26SEC EDGARSanford S. Zweifach, Board member
- 27SEC EDGARBogdan Dziurzynski, Board member
- 28SEC EDGARDebra Odink, Board member
- 29SEC EDGARSamuel D. Isaly, Board member
- 30SEC EDGARA. Rachel Leheny, Board member
- 31SEC EDGARAnnette Bianchi, Board member
- 32SEC EDGARChristopher S. Henney, Board member
- 33SEC EDGARDaniel K. Spiegelman, Board member
- 34SEC EDGARDonald J. Santel, Board member
- 35SEC EDGARJames Healy, Board member